Published in Arthritis Res Ther on December 07, 2009
The contribution of disease activity on functional limitations over time through psychological mediators: a 12-month longitudinal study in patients with ankylosing spondylitis. Rheumatology (Oxford) (2011) 0.91
Physical activity assessment in patients with axial spondyloarthritis compared to healthy controls: a technology-based approach. PLoS One (2014) 0.82
Towards a better understanding of the role of psychological variables in arthritis outcome research. Arthritis Res Ther (2010) 0.81
Moving instead of asking? Performance-based tests and BASFI-questionnaire measure different aspects of physical function in ankylosing spondylitis. Arthritis Res Ther (2012) 0.79
A primary analysis of sexual problems in Chinese patients with ankylosing spondylitis. Rheumatol Int (2012) 0.79
Learned helplessness predicts functional disability, pain and fatigue in patients with recent-onset inflammatory polyarthritis. Rheumatology (Oxford) (2013) 0.77
The relationship between disease activity measured by the BASDAI and psychological status, stressful life events, and sleep quality in ankylosing spondylitis. Clin Rheumatol (2014) 0.77
Relationship between psychiatric status, self-reported outcome measures, and clinical parameters in axial spondyloarthritis. Medicine (Baltimore) (2014) 0.77
Accelerometry-Based Activity Recognition and Assessment in Rheumatic and Musculoskeletal Diseases. Sensors (Basel) (2016) 0.75
Coping with Stress and Body Image in Patients with Ankylosing Spondylitis. Noro Psikiyatr Ars (2014) 0.75
Anxiety and depression correlate with disease and quality-of-life parameters in Chinese patients with ankylosing spondylitis. Patient Prefer Adherence (2016) 0.75
Positive and negative affective states and disease activity in ankylosing spondylitis. Rheumatol Int (2014) 0.75
The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med (2001) 76.04
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol (1994) 11.17
A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol (1994) 8.61
The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment. Pain (1983) 5.83
Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ (2002) 4.92
Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). J Affect Disord (2004) 4.66
Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol (1994) 4.00
Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med (2002) 2.67
Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol (2000) 2.45
Coping with rheumatoid arthritis pain: catastrophizing as a maladaptive strategy. Pain (1989) 2.44
Development of a questionnaire for the assessment of active and passive coping strategies in chronic pain patients. Pain (1987) 2.15
The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol (1997) 2.13
Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res (1999) 2.00
Coping with chronic pain: a critical review of the literature. Pain (1991) 2.00
The role of pain coping strategies in prognosis after whiplash injury: passive coping predicts slowed recovery. Pain (2006) 1.85
The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum (1998) 1.80
Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol (1985) 1.74
The measurement of helplessness in rheumatoid arthritis. The development of the arthritis helplessness index. J Rheumatol (1985) 1.55
The development and psychometric evaluation of the Brief Resilient Coping Scale. Assessment (2004) 1.50
The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology (Oxford) (2007) 1.47
Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum (2002) 1.41
Quality of life in patients with ankylosing spondylitis. Rheum Dis Clin North Am (1998) 1.37
Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol (2003) 1.36
Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum (2005) 1.26
Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors. Arthritis Rheum (1990) 1.25
Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions. J Rheumatol (2005) 1.24
Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol (2002) 1.23
Active and passive coping strategies in chronic pain patients. Pain (1996) 1.22
Factor structure of the Arthritis Helplessness Index. J Rheumatol (1988) 1.20
Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford) (2005) 1.18
Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. Scand J Rheumatol (2006) 1.14
Disease and psychological status in ankylosing spondylitis. Rheumatology (Oxford) (2006) 1.12
Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol (2001) 1.11
Association of depression and rheumatoid arthritis. Psychosomatics (2003) 1.08
Psychosocial predictors of functional change in recently diagnosed rheumatoid arthritis patients. Behav Res Ther (1998) 1.08
Socioeconomic status in ankylosing spondylitis: relationship between occupation and disease activity. J Rheumatol (1997) 1.04
Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases. Psychosom Med (2004) 1.00
Disability and coping as predictors of psychological adjustment to rheumatoid arthritis. J Consult Clin Psychol (1989) 0.99
Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthritis Rheum (2007) 0.93
Prediction of pain behavior and functional status of rheumatoid arthritis patients using medical status and psychological variables. Pain (1988) 0.91
The value of screening for psychiatric disorders in rheumatology referrals. Arch Intern Med (1998) 0.90
Role of contextual factors in health-related quality of life in ankylosing spondylitis. Ann Rheum Dis (2010) 0.87
Problem elicitation to assess patient priorities in ankylosing spondylitis and fibromyalgia. J Rheumatol (1995) 0.86
Work status among patients with ankylosing spondylitis in Argentina. J Clin Rheumatol (2008) 0.84
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum (2008) 13.08
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med (2006) 10.95
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med (2005) 6.83
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med (2002) 6.26
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet (2011) 5.56
New therapies for treatment of rheumatoid arthritis. Lancet (2007) 4.80
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Patient participation in medical consultations: why some patients are more involved than others. Med Care (2005) 3.68
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet (2010) 3.58
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
Gene and pathway-based second-wave analysis of genome-wide association studies. Eur J Hum Genet (2010) 3.03
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum (2005) 2.76
Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum (2006) 2.75
Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum (2011) 2.74
The shortened disabilities of the arm, shoulder and hand questionnaire (QuickDASH): validity and reliability based on responses within the full-length DASH. BMC Musculoskelet Disord (2006) 2.67
Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet (2010) 2.61
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet (2011) 2.54
Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum (2009) 2.50
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum (2008) 2.48
Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet (2010) 2.44
Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum (2013) 2.42
The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum (2013) 2.40
Genome sequence of the saprophyte Leptospira biflexa provides insights into the evolution of Leptospira and the pathogenesis of leptospirosis. PLoS One (2008) 2.35
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum (2005) 2.32
A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum (2007) 2.24
Imaging of intraarticular masses. Radiographics (2005) 2.24
Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA (2007) 2.17
Progress toward the cure of rheumatoid arthritis? The BeSt study. Arthritis Rheum (2005) 2.15
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum (2005) 2.03
ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med (2007) 1.94
Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis (2009) 1.84
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.84
Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA (2003) 1.81
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80
Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. JACC Cardiovasc Imaging (2011) 1.75
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum (2004) 1.75
Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med (2007) 1.73
Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum (2013) 1.72
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum (2011) 1.70
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis (2007) 1.69
Avulsion fractures of the knee: imaging findings and clinical significance. Radiographics (2008) 1.66
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum (2005) 1.64
Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum (2006) 1.64
Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum (2008) 1.64
New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Rheumatol (2014) 1.64
The physician Hans Reiter as prisoner of war in Nuremberg: a contextual review of his interrogations (1945-1947). Semin Arthritis Rheum (2003) 1.64
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum (2002) 1.62
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol (2014) 1.62
The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol (2007) 1.62
IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci U S A (2011) 1.61
A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Rheum (2009) 1.59
Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol (2002) 1.57
The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther (2003) 1.56
Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum (2007) 1.53
A multidimensional model of fatigue in patients with rheumatoid arthritis. J Rheumatol (2012) 1.52
Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum (2012) 1.52
Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum (2007) 1.51
Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther (2010) 1.50
Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet (2011) 1.49
Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum (2006) 1.47
Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis (2006) 1.47
Complications of the spine in ankylosing spondylitis with a focus on deformity correction. Neurosurg Focus (2008) 1.44
Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol (2013) 1.43
Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum (2009) 1.43
Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet (2010) 1.43
Suicidal ideation among adults with arthritis: prevalence and subgroups at highest risk. Data from the 2007-2008 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken) (2011) 1.42
Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine. J Rheumatol (2009) 1.42
Association of an ERAP1 ERAP2 haplotype with familial ankylosing spondylitis. Ann Rheum Dis (2009) 1.42
Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet (2012) 1.41
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis (2011) 1.41
Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum (2010) 1.40